Fadi Aldaas, MD
Critical Care Medicine · Chicago Ridge, ILNPI 1417245499
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (58.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.5% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2024 at $9,563 and has fallen 82.7% since, to $1,657 in 2025. Among critical care medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 382 payments — averaging $47.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- GSK$2K
- AstraZeneca$1K
- Sanofi$591
- Grifols USA, LLC$415
- Boehringer Ingelheim$383
- plus $2K from 24 others
What the payments were for
- Travel & lodging$3612%
- Food & beverage$7,17139%
- Education$10,73259%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 22 | $11,226 |
| GSK | 145 | $1,851 |
| AstraZeneca | 43 | $1,322 |
| Sanofi | 28 | $591 |
| Grifols USA, LLC | 17 | $415 |
| Boehringer Ingelheim | 14 | $383 |
| Jazz Pharmaceuticals Inc. | 5 | $333 |
| Electromed, Inc. | 23 | $294 |
| Insmed, Inc. | 19 | $260 |
| Olympus America Inc. | 3 | $178 |
| Actelion Pharmaceuticals US, Inc. | 6 | $171 |
| Regeneron Healthcare Solutions, Inc. | 8 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $159 |
| Sanofi-aventis U.S. LLC | 2 | $155 |
| Inogen, Inc. | 8 | $153 |
| Genentech USA, Inc. | 5 | $94 |
| Amgen | 4 | $79 |
| Baxter Healthcare | 4 | $70 |
| Pulmonx Corporation | 1 | $62 |
| Sunovion Pharmaceuticals Inc. | 3 | $51 |
| Philips North America LLC | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Merck | 2 | $36 |
| Novartis | 1 | $25 |
| Abiomed | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Phadia US Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,264 in reported general payments places this provider in the 95th percentile of 281 critical care medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 30 | $397,422 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 245 | $248,548 |
| Dupixent PenDupilumab | 39 | $148,900 |
| Dupixent SyringeDupilumab | 25 | $94,768 |
| NucalaMepolizumab | 25 | $93,960 |
| Fasenra PenBenralizumab | 12 | $68,575 |
| Breo ElliptaFluticasone/Vilanterol | 80 | $57,852 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $31,939 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $27,488 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $13,820 |
| Spiriva RespimatTiotropium Bromide | 15 | $13,783 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $12,504 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $11,171 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $8,639 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $7,997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,851 | $440,352416 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $383 | $425,02462 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,322 | $40,57874 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 critical care medicine providers in Illinois.
Other critical care medicine in Chicago Ridge
- Anas NahhasChicago Ridge$9K
- Dinas AleksonisChicago Ridge$4K
- Eyad KarzounChicago Ridge$3K
- Brian ReichardtO Fallon$892K
- Michael CutticaChicago$402K
- Daniel DillingMaywood$208K
- Israel RubinsteinChicago$107K
- John RickelmanQuincy$90K
- Abbas Al-QamariChicago$40K
- Husam NayefPalos Park$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.